西藏诺迪康药业股份有限公司 关于为全资子公司提供担保的进展公告

Summary of Key Points Core Viewpoint - The company has provided a guarantee of RMB 41 million for its wholly-owned subsidiary, Tibet Nodi Kang Biomedical Sales Co., Ltd., with a total guarantee balance of RMB 191 million as of the announcement date [1][5]. Group 1: Guarantee Overview - The company has signed a guarantee contract with Bank of China, Shannan Branch, to provide a joint liability guarantee for the subsidiary's credit business, not exceeding RMB 41 million [5]. - The subsidiary has provided counter-guarantees to the company [2][9]. - There are no overdue guarantees reported [3]. Group 2: Internal Decision-Making Process - The company held board meetings on March 13, 2025, and April 8, 2025, to approve the guarantee and credit limit for the subsidiary, allowing a total credit limit of up to RMB 1 billion for the year 2025 [6]. - The approval process for the guarantee is within the authorized limits and complies with relevant regulations [6]. Group 3: Subsidiary Information - Tibet Nodi Kang Biomedical Sales Co., Ltd. was established on July 25, 2022, with a registered capital of RMB 28 million [7]. - The company holds 100% ownership of the subsidiary [8]. Group 4: Guarantee Agreement Details - The guarantee covers all debts under the main contract, including principal, interest, penalties, and other related costs [8][9]. - The guarantee period lasts for three years from the maturity of the main debt [9]. Group 5: Overall Guarantee Situation - The total external guarantees provided by the company and its subsidiaries amount to RMB 800 million, representing 20.24% of the latest audited net assets [10]. - The actual balance of guarantees is RMB 541 million, accounting for 13.69% of the latest audited net assets [10].